Spots Global Cancer Trial Database for early breast cancer
Every month we try and update this database with for early breast cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer | NCT00431080 | Breast Cancer | Docetaxel Paclitaxel Epirubicin Cyclophosphamid... 5-fluoruracil Granulocyte-col... | 18 Years - 75 Years | Hellenic Oncology Research Group | |
| Innovative "Scoring System" in Breast Cancer Post Neoadiuvant Chemotherapy | NCT05213403 | Early Breast Ca... | Evaluation with... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Liver Safety Under Upfront Arimidex vs Tamoxifen | NCT00537771 | Breast Cancer | Anastrozole Tamoxifen | - | AstraZeneca | |
| CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER | NCT03712956 | Breast Cancer | Caelyx® | 18 Years - 70 Years | European Institute of Oncology | |
| Functional Anatomical Examination of Axillary Sentinel Lymph Node Drainage in the Axillary Subregions in Early Breast Cancer | NCT01804309 | Breast Cancer | Sentinel lymph ... | 18 Years - | National Institute of Oncology, Hungary | |
| Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study | NCT00553358 | Neoplasms, Brea... | Lapatinib Trastuzumab Paclitaxel | 18 Years - | Novartis | |
| A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04) | NCT02187744 | Early Breast Ca... | PF-05280014 Taxotere® Paraplatin® Trastuzumab-EU Taxotere® Paraplatin® | 18 Years - | Pfizer | |
| Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer | NCT00615602 | Breast Cancer | Docetaxel Trastuzumab Epirubicin Cyclophosphamid... 5-fluoruracil Granulocyte-col... Trastuzumab | 18 Years - 75 Years | Hellenic Oncology Research Group | |
| Adjuvant FEC Versus EP in Breast Cancer (MIG5) | NCT02450058 | Breast Cancer Chemotherapy, A... | 5-fluorouracil epirubicin cyclophosphamid... epirubicin paclitaxel | 18 Years - 70 Years | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | |
| Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC | NCT04565054 | Breast Cancer F... | Abemaciclib 50 ... | 18 Years - | West German Study Group | |
| A Window-of-opportunity Study of Pelareorep in Early Breast Cancer | NCT04102618 | Breast Cancer | Pelareorep Letrozole Atezolizumab Trastuzumab | 18 Years - | Oncolytics Biotech | |
| Aromatherapy in the Treatment of Early Breast Cancer | NCT06435104 | Early Breast Ca... | neoadjuvant che... aromatherapy | 18 Years - 80 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Quality of Life in Chinese Postmenopausal HR(+) Early Breast Cancer (EBC) Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment | NCT01144572 | Breast Cancer | 50 Years - 70 Years | AstraZeneca | ||
| A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | NCT04961996 | Early Breast Ca... | Giredestrant Endocrine Thera... LHRH Agonist Abemaciclib | 18 Years - | Hoffmann-La Roche | |
| A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer. | NCT01792726 | Early Breast Ca... | Boost to the tu... | - | University College, London | |
| Arimidex Therapy Compliance Electronic Monitoring System | NCT00936442 | Breast Cancer | Anastrozole Educational mat... | - | AstraZeneca | |
| Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer | NCT00431080 | Breast Cancer | Docetaxel Paclitaxel Epirubicin Cyclophosphamid... 5-fluoruracil Granulocyte-col... | 18 Years - 75 Years | Hellenic Oncology Research Group | |
| Effect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer | NCT06152471 | Early-stage Bre... Diarrhea Adverse Drug Ev... | SPC-flakes Salovum Placebo | 18 Years - | Uppsala University Hospital | |
| Axillary Reverse Mapping Using Methylene Blue Subcutaneous Injection Can Identify Arm Lymph Nodes and Vessels, Measuring Arm Size for Lymphedema, Histopathological Examination of Arm Lymph Nodes Included With Axillary Lymph Node Dissection | NCT04137744 | Arm Lymphedema Lymphatic Sprea... Early Breast Ca... | AXILLARY REVERS... | 18 Years - | Zagazig University | |
| A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer | NCT05415215 | Early Breast Ca... Locally Advance... Inflammatory Br... | Fixed Dose Comb... Pertuzumab IV Trastuzumab IV Trastuzumab Emt... Investigator's ... Surgery Radiotherapy | 18 Years - | Hoffmann-La Roche | |
| Aromatherapy in the Treatment of Early Breast Cancer | NCT06435104 | Early Breast Ca... | neoadjuvant che... aromatherapy | 18 Years - 80 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Evaluation of Brain Function Before and After Standard Chemotherapy for Early Breast Cancer | NCT00713141 | Early Breast Ca... | 18 Years - | National University Hospital, Singapore | ||
| QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer | NCT06404736 | Early Breast Ca... Neoadjuvant The... TNBC, Triple Ne... | Bispecific anti... Albumin-bound p... Carboplatin | 18 Years - 70 Years | Fudan University | |
| A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer. | NCT01792726 | Early Breast Ca... | Boost to the tu... | - | University College, London | |
| Innovative "Scoring System" in Breast Cancer Post Neoadiuvant Chemotherapy | NCT05213403 | Early Breast Ca... | Evaluation with... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients | NCT01446185 | Breast Cancer | Oncotype DX bre... | 18 Years - | Genomic Health®, Inc. | |
| Aromatherapy in the Treatment of Early Breast Cancer | NCT06435104 | Early Breast Ca... | neoadjuvant che... aromatherapy | 18 Years - 80 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer) | NCT04436744 | Early Breast Ca... | Giredestrant Anastrozole Palbociclib Surgery | 18 Years - | Hoffmann-La Roche | |
| Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer | NCT04659499 | Early Breast Ca... | Nab-paclitaxel ... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence | NCT01081509 | Breast Cancer | - | AstraZeneca | ||
| FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy | NCT06185569 | Breast Cancer | 18 Years - | Centre Hospitalier Universitaire de Besancon | ||
| NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) | NCT06081244 | Triple Negative... | Sacituzumab gov... Pembrolizumab | 18 Years - | West German Study Group | |
| A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients | NCT03013504 | HER2 Positive B... | HD201 Herceptin Docetaxel Epirubicin Cyclophosphamid... | 18 Years - | Prestige Biopharma Limited | |
| Prospective Research for Elderly (≥65 Years Old) Early Breast Cancer Patients | NCT05680194 | Breast Cancer F... | operation Bisphosphonate | 65 Years - 100 Years | Peking Union Medical College Hospital | |
| Tolerance of PICC Line Versus Implanted Port for Adjuvant Chemotherapy in Early Breast Cancer | NCT02095743 | Early Stage Bre... | implanted port ... Use of a PICC l... | 18 Years - | Centre Henri Becquerel | |
| Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer | NCT03520894 | Early Breast Ca... | Neoadjuvant rad... | 50 Years - | Azienda Ospedaliero-Universitaria Careggi | |
| Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD) | NCT03949634 | Early Breast Ca... | PLD CTX Docetaxel Paclitaxel Doxorubicin | 18 Years - 75 Years | Fudan University | |
| Quality of Life in Chinese Postmenopausal HR(+) Early Breast Cancer (EBC) Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment | NCT01144572 | Breast Cancer | 50 Years - 70 Years | AstraZeneca | ||
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer) | NCT04436744 | Early Breast Ca... | Giredestrant Anastrozole Palbociclib Surgery | 18 Years - | Hoffmann-La Roche | |
| Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer | NCT02308085 | Early Breast Ca... | Endocrine thera... | 18 Years - 42 Years | ETOP IBCSG Partners Foundation | |
| Tolerance of PICC Line Versus Implanted Port for Adjuvant Chemotherapy in Early Breast Cancer | NCT02095743 | Early Stage Bre... | implanted port ... Use of a PICC l... | 18 Years - | Centre Henri Becquerel | |
| Feasibility of Ambulatory Surgery for Early Breast Cancer | NCT01613352 | Early Breast Ca... Psychosocial We... Ambulatory Surg... | Ambulatory surg... | 18 Years - 90 Years | Helsinki University Central Hospital | |
| Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) | NCT01077154 | Breast Cancer | Placebo Denosumab | 18 Years - | Amgen | |
| A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer | NCT03493854 | Early Breast Ca... | Cyclophosphamid... Doxorubicin Docetaxel Paclitaxel Pertuzumab IV FDC of Pertuzum... Trastuzumab IV Trastuzumab SC Surgery Post-operative ... Hormone Therapy | 18 Years - | Hoffmann-La Roche | |
| Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer | NCT06341894 | Early Breast Ca... | Dalpiciclib Endocrine thera... | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC) | NCT02738970 | Early Breast Ca... | Trastuzumab Pertuzumab | 18 Years - 45 Years | Hoffmann-La Roche | |
| Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC | NCT04055493 | Breast Cancer F... | Ribociclib 200M... | 18 Years - | West German Study Group | |
| Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab | NCT06371807 | Early Breast Ca... Triple Negative... | Pembrolizumab i... | 18 Years - 100 Years | Fundacao Champalimaud | |
| Feasibility Study of Stereotactic Body Radiotherapy for Early Breast Cancer | NCT02065960 | Breast Neoplasm | Stereotactic bo... | 70 Years - | Juravinski Cancer Center | |
| Electronic Study for Anastrozole Pharmacovigilance Evaluation | NCT00558168 | Early Breast Ca... | - | AstraZeneca | ||
| Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer | NCT00455533 | Breast Cancer | Ixabepilone Paclitaxel Cyclophosphamid... Doxorubicin | 18 Years - | Bristol-Myers Squibb | |
| Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Early Breast Cancer Patients | NCT05730647 | Early Breast Ca... | None interventi... | 18 Years - | Consorzio Oncotech | |
| NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) | NCT06081244 | Triple Negative... | Sacituzumab gov... Pembrolizumab | 18 Years - | West German Study Group | |
| Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women. | NCT00287534 | Breast Cancer | Anastrozole Tamoxifen | - 75 Years | AstraZeneca | |
| Single Pre-Operative Radiation Therapy (SPORT) for Low Risk Breast Cancer | NCT01717261 | Breast Cancer | Single Pre-Oper... | 60 Years - | Maisonneuve-Rosemont Hospital | |
| A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) | NCT03988036 | Breast Cancer | Pembrolizumab Trastuzumab Bio... Pertuzumab | 18 Years - | West German Study Group | |
| Quality of Life in Chinese Postmenopausal HR(+) Early Breast Cancer (EBC) Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment | NCT01144572 | Breast Cancer | 50 Years - 70 Years | AstraZeneca | ||
| Single Pre-Operative Radiation Therapy (SPORT) for Low Risk Breast Cancer | NCT01717261 | Breast Cancer | Single Pre-Oper... | 60 Years - | Maisonneuve-Rosemont Hospital | |
| Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC | NCT04055493 | Breast Cancer F... | Ribociclib 200M... | 18 Years - | West German Study Group | |
| GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel | NCT04538833 | Early Breast Ca... | monosialic gang... Placebo | 18 Years - 75 Years | Henan Cancer Hospital | |
| To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer. | NCT03658213 | Breast Cancer | ZOLADEX 10.8 mg ZOLADEX 3.6mg | 18 Years - 59 Years | AstraZeneca | |
| Accelerated Partial Breast Irradiation for Early Breast Cancer | NCT00418210 | Breast Cancer | Accelerated par... | 50 Years - | Trans Tasman Radiation Oncology Group | |
| Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer | NCT03351062 | Breast Cancer F... | Tamoxifen Toremifene | 18 Years - 50 Years | Chinese Anti-Cancer Association | |
| Activity Program During Aromatase Inhibitor Therapy | NCT03786198 | Early Breast Ca... | Activity progra... Control | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA) | NCT02802748 | Breast Cancer | Oral Vinorelbin... Letrozole | 18 Years - | SOLTI Breast Cancer Research Group | |
| A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients | NCT03013504 | HER2 Positive B... | HD201 Herceptin Docetaxel Epirubicin Cyclophosphamid... | 18 Years - | Prestige Biopharma Limited | |
| The Benefits of Continued Use of Ovarian Function Suppression After 5 Years | NCT06050109 | Breast Cancer F... Endocrine Thera... | OFS continues t... Immunohistochem... | 18 Years - 60 Years | Hubei Cancer Hospital | |
| Aromatherapy in the Treatment of Early Breast Cancer | NCT06435104 | Early Breast Ca... | neoadjuvant che... aromatherapy | 18 Years - 80 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer | NCT03493854 | Early Breast Ca... | Cyclophosphamid... Doxorubicin Docetaxel Paclitaxel Pertuzumab IV FDC of Pertuzum... Trastuzumab IV Trastuzumab SC Surgery Post-operative ... Hormone Therapy | 18 Years - | Hoffmann-La Roche | |
| Arthralgia During Anastrozole Therapy for Breast Cancer | NCT00323479 | Early Breast Ca... | Anastrozole | 18 Years - | AstraZeneca | |
| HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer. | NCT00412022 | Breast Cancer | tamoxifen triptorelin letrozole zoledronic acid | 18 Years - | National Cancer Institute, Naples | |
| A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04) | NCT02187744 | Early Breast Ca... | PF-05280014 Taxotere® Paraplatin® Trastuzumab-EU Taxotere® Paraplatin® | 18 Years - | Pfizer | |
| Laser Therapy for Vulvovaginal Symptoms in Breast Cancer Patients | NCT03628092 | Vulvovaginal At... Genitourinary S... | CO2 Fractional ... Placebo | 18 Years - | Royal North Shore Hospital | |
| Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer | NCT00330317 | Breast Cancer | letrozole | 18 Years - 80 Years | Novartis | |
| Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer | NCT03520894 | Early Breast Ca... | Neoadjuvant rad... | 50 Years - | Azienda Ospedaliero-Universitaria Careggi | |
| Adjuvant FEC Versus EP in Breast Cancer (MIG5) | NCT02450058 | Breast Cancer Chemotherapy, A... | 5-fluorouracil epirubicin cyclophosphamid... epirubicin paclitaxel | 18 Years - 70 Years | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | |
| Trial of Tomotherapy in Breast Cancer | NCT00459628 | Breast Neoplasm... | Conventional ra... Tomotherapy | 18 Years - | Vrije Universiteit Brussel | |
| QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer | NCT06404736 | Early Breast Ca... Neoadjuvant The... TNBC, Triple Ne... | Bispecific anti... Albumin-bound p... Carboplatin | 18 Years - 70 Years | Fudan University | |
| Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) | NCT01077154 | Breast Cancer | Placebo Denosumab | 18 Years - | Amgen | |
| Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer | NCT00357110 | Breast Cancer | Fulvestrant Anastrozole | - | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
